Pharmaniaga Berhad (467709-M)

UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENT

For the quarter ended 31 December 2014	Current Period		Cumulative Period	
(All figures are stated in RM'000)	2014	2013	2014	2013
Revenue	**627,103**	567,860	**2,122,933**	1,946,639
Cost of sales	**(525,410)**	(482,997)	**(1,773,473)**	(1,649,040)
Gross profit	**101,693**	84,863	**349,460**	297,599
Other income/(expense)	**338**	(418)	**808**	598
Operating expenses	**(59,204)**	(48,161)	**(209,211)**	(191,787)
Finance costs	**(5,449)**	(3,757)	**(16,768)**	(14,665)
Interest income	**476**	480	**1,291**	1,252
Profit before taxation	**37,854**	33,007	**125,580**	92,997
Taxation	**(1,233)**	(11,740)	**(31,355)**	(36,236)
Profit for the period/year	**36,621**	21,267	**94,225**	56,761
Profit for the period/year attributable to:				
Owners of the parent	**36,697**	20,813	**93,844**	55,200
Non-controlling interests	**(76)**	454	**381**	1,561
Profit for the period/year	**36,621**	21,267	**94,225**	56,761
Earnings per share - sen				
Basic and diluted	**14.18**	8.04	**36.25**	21.32

The Unaudited Condensed Consolidated Income Statement should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.

Pharmaniaga Berhad (467709-M)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (CONTINUED)

For the quarter ended 31 December 2014	**Current Period**		**Cumulative Period**	
(All figures are stated in RM'000)	**2014**	**2013**	**2014**	**2013**
Profit for the period/year	**36,621**	21,267	**94,225**	56,761
Other comprehensive income/(loss), net of tax				
Foreign currency translation difference in respect of foreign operations	**4,981**	(1,260)	**3,230**	(5,588)
Recognition of actuarial gains	**201**	1,225	**201**	1,225
	5,182	**(35)**	**3,431**	**(4,363)**
Total comprehensive income for the period/year	**41,803**	**21,232**	**97,656**	**52,398**
Attributable to:				
Owners of the parent	**40,767**	20,794	**96,352**	52,801
Non-controlling interests	**1,036**	438	**1,304**	(403)
Total comprehensive income for the period/year	**41,803**	21,232	**97,656**	52,398

The Unaudited Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.

Pharmaniaga Berhad (467709-M)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	As at 31 December 2014	As at 31 December 2013
(All figures are stated in RM'000)		
ASSETS		
Non-current assets		
Property, plant and equipment	369,800	353,368
Prepaid lease payments	2,547	1,075
Investment in an associate	-	19
Intangible assets	232,982	124,508
Receivables	12,055	11,049
Deferred tax assets	21,070	6,625
	638,454	496,644
Current assets		
Inventories	427,035	410,531
Receivables	142,916	157,776
Tax recoverable	2,333	13,215
Deposits, cash and bank balances	31,982	32,900
	604,266	614,422
TOTAL ASSETS	1,242,720	1,111,066
EQUITY AND LIABILITIES		
Equity attributable to equity holders of the Company		
Share capital	129,441	129,441
Reserves	397,071	358,191
Shareholders' equity	526,512	487,632
Non-controlling interests	25,523	15,631
Total equity	552,035	503,263
Non-current liabilities		
Loans and borrowings	1,060	318
Deferred tax liabilities	28,290	12,834
Provision for defined benefit plan	6,213	4,789
	35,563	17,941
Current liabilities		
Payables	448,554	387,404
Amount due to immediate holding company	227	200
Current tax liabilities	6,109	2,696
Deferred income	152	-
Loans and borrowings	200,080	199,562
	655,122	589,862
Total liabilities	690,685	607,803
TOTAL EQUITY AND LIABILITIES	1,242,720	1,111,066

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.

Pharmaniaga Berhad (467709-M)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Attributable to shareholders of the Company						
For the year ended 31 December 2014	**Share Capital**	***Share Premium**	***Exchange Reserve**	**Retained Earnings**	**Total**	**Non-controlling Interests**	**Total Equity**
(All figures are stated in RM'000)							
At 1 January 2014	**129,441**	**11,751**	**(4,131)**	**350,571**	**487,632**	**15,631**	**503,263**
Total comprehensive income for the year	**-**	**-**	**2,401**	**93,951**	**96,352**	**1,304**	**97,656**
Transactions with owners							
Dividends	-	-	-	**(57,472)**	**(57,472)**	**-**	**(57,472)**
Acquisition of a subsidiary	-	-	-	**-**	**-**	**8,402**	**8,402**
Issue of shares by a subsidiary	-	-	-	**-**	**-**	**186**	**186**
At 31 December 2014	**129,441**	**11,751**	**(1,730)**	**387,050**	**526,512**	**25,523**	**552,035**
At 1 January 2013	117,674	11,751	(1,058)	343,651	472,018	15,835	487,853
Total comprehensive income for the year	-	-	(3,073)	55,874	52,801	(403)	52,398
Transactions with owners							
Bonus issue	11,767	-	-	(11,767)	-	-	-
Non-controlling interest arising on incorporation of a new subsidiary	-	-	-	-	-	199	199
Dividends	-	-	-	(37,187)	(37,187)	-	(37,187)
At 31 December 2013	129,441	11,751	(4,131)	350,571	487,632	15,631	503,263

* Denotes non distributable reserves

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.

Pharmaniaga Berhad (467709-M)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the quarter ended 31 December 2014

(All figures are stated in RM'000)	2014	2013
Operating Activities		
Cash receipts from customers	**2,150,779**	1,947,477
Cash payments to suppliers and employees	**(1,900,696)**	(1,644,064)
Net cash generated from operations	**250,083**	303,413
Interest paid	**(16,573)**	(16,149)
Tax paid	**(21,338)**	(33,578)
Interest received	**1,307**	1,213
Net cash generated from operating activities	**213,479**	254,899
Investing Activities		
Acquisition of a subsidiary	**(69,264)**	(4,505)
Issue of shares by a subsidiary	**186**	-
Settlement on novation consideration	**-**	(21,083)
Purchase of property, plant and equipment	**(31,434)**	(43,514)
Purchase of intangible assets	**(54,649)**	(15,205)
Proceeds from disposal of property, plant and equipment	**619**	301
Net cash used in investing activities	**(154,542)**	(84,006)
Financing Activities		
Dividend paid	**(57,472)**	(37,187)
Net repayment of borrowings	**(2,633)**	(134,128)
Net cash used in financing activities	**(60,105)**	(171,315)
Net decrease in cash and cash equivalents	**(1,168)**	(422)
Effects of exchange rate changes	**250**	(1,231)
Cash and cash equivalent at beginning of year	**32,900**	34,553
Cash and cash equivalent at end of year	**31,982**	32,900
Analysis of cash and cash equivalents		
Deposits, cash and bank balances	**31,982**	32,900

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the accompanying explanatory notes attached to these interim financial statements.

Part A - Explanatory Notes Pursuant to Malaysian Financial Reporting Standard 134 ("MFRS 134")

A1. Basis of Preparation

These unaudited condensed consolidated interim financial statements for the year ended 31 December 2014 have been prepared in accordance with MFRS134 Interim Financial Reporting, IAS 34 Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad.

These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited financial statements for the financial year ended 31 December 2013. The explanatory notes attached to these condensed consolidated interim financial statements provide an explanation of events and transaction that are significant to an understanding of the changes in the financial position and performance of the Group since the year ended 31 December 2013.

A2. Significant Accounting Policies

The significant accounting policies adopted are consistent with those of the audited financial statements for the year ended 31 December 2013, except for the adoption of the following Amendments to Malaysian Financial Reporting Standards (MFRSs) which are applicable for the Group's financial period beginning 1 January 2014.

A2.1 Adoption of Amendments to MFRSs

On 1 January 2014, the Group adopted the following Amendments to MFRSs:-

Amendments to MFRS 132	Financial Instruments : Presentation
Amendments to MFRS 136	Recoverable Amount Disclosures for Non-Financial Assets
Amendments to MFRS 10, MFRS 12 and MFRS 127	Investment Entities

Adoption of the above Amendments to MFRSs did not have any material effect on the financial performance, position or presentation of the Group.

A2.2 MFRSs and Amendments to MFRSs issued but not yet effective

At the date of authorisation of these interim financial statements, the following MFRSs and Amendments to MFRSs were issued but not yet effective and have not been applied by the Group:

a) Financial year beginning on/after 1 January 2016

i) Amendments to MFRS 116 'Property, plant and equipment' and MFRS 138 'Intangible assets' (effective from 1 January 2016) clarify that the use of revenue-based methods to calculate the depreciation and amortisation of an item of property, plant and equipment and intangible are not appropriate. This is because revenue generated by an activity that includes the use of an asset generally reflects factors other than the consumption of the economic benefits embodied in the asset.

The amendments to MFRS 138 also clarify that revenue is generally presumed to be an inappropriate basis for measuring the consumption of the economic benefits embodied in an intangible asset. This presumption can be overcome only in the limited circumstances where the intangible asset is expressed as a measure of revenue or where it can be demonstrated that revenue and the consumption of the economic benefits of the intangible asset are highly correlated.

ii) Amendments to MFRS 10 and MFRS 128 regarding sale or contribution of assets between an investor and its associate or joint venture (effective from 1 January 2016) resolve a current inconsistency between MFRS 10 and MFRS 128. The accounting treatment depends on whether the non-monetary assets sold or contributed to an associate or joint venture constitute a 'business'. Full gain or loss shall be recognised by the investor where the non-monetary assets constitute a 'business'. If the assets do not meet the definition of a business, the gain or loss is recognised by the investor to the extent of the other investors' interests. The amendments will only apply when an investor sells or contributes assets to its associate or joint venture. They are not intended to address accounting for the sale or contribution of assets by an investor in a joint operation.

b) Financial year beginning on/after 1 January 2017

MFRS 15 'Revenue from contracts with customers' (effective from 1 January 2017) deals with revenue recognition and establishes principles for reporting useful information to users of financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. Revenue is recognised when a customer obtains control of a good or service and thus has the ability to direct the use and obtain the benefits from the good or service. The standard replaces MFRS 118 'Revenue' and MFRS 111 'Construction contracts' and related interpretations.

A2. Significant Accounting Policies (Continued)

A2.2 MFRSs and Amendments to MFRSs issued but not yet effective (continued)

c) Financial year beginning on/after 1 January 2018

MFRS 9 ‘Financial Instruments’ (effective from 1 January 2018) will replace MFRS 139 "Financial Instruments: Recognition and Measurement". The complete version of MFRS 9 was issued in November 2014.

MFRS 9 retains but simplifies the mixed measurement model in MFRS 139 and establishes three primary measurement categories for financial assets: amortised cost, fair value through profit or loss and fair value through other comprehensive income ("OCI"). The basis of classification depends on the entity's business model and the contractual cash flow characteristics of the financial asset. Investments in equity instruments are always measured at fair value through profit or loss with a irrevocable option at inception to present changes in fair value in OCI (provided the instrument is not held for trading). A debt instrument is measured at amortised cost only if the entity is holding it to collect contractual cash flows and the cash flows represent principal and interest.

For liabilities, the standard retains most of the MFRS 139 requirements. These include amortised cost accounting for most financial liabilities, with bifurcation of embedded derivatives. The main change is that, in cases where the fair value option is taken for financial liabilities, the part of a fair value change due to an entity’s own credit risk is recorded in other comprehensive income rather than the income statement, unless this creates an accounting mismatch.

There is now a new expected credit losses model on impairment for all financial assets that replaces the incurred loss impairment model used in MFRS 139. The expected credit losses model is forward-looking and eliminates the need for a trigger event to have occurred before credit losses are recognised.

The Group will adopt the above pronouncements when they become effective in the respective financial periods. These pronouncements are not expected to have any material effect to the financial statements of the Group upon their initial application.

A3. Audit report in respect of the 2013 financial statements

The audit report on the Group’s financial statements for the financial year ended 31 December 2013 was not qualified.

A4. Seasonal or cyclical factors

The Group’s operations are not subject to any significant seasonal or cyclical factors.

A5. Unusual items due to their nature, size or incidence

There were no unusual items affecting assets, liabilities, equity, net income, or cash flows during the year under review.

A6. Change in Estimates

There were no material changes in estimates of amounts reported in the current financial year or the previous financial year.

A7. Debt and equity securities

There were no issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares in the current financial year.

A8. Dividends

On 2 April 2014, the Company paid a fourth interim dividend of 6.20 sen (2012: 4.55 sen) per share in respect of the financial year ended 31 December 2013 amounting to RM16.0 million (2012: RM11.8 million).

On 16 June 2014, the Company paid a first interim dividend of 4.00 sen (2013: 3.41 sen) per share in respect of the financial year ended 31 December 2014 amounting to RM10.4 million (2013: RM8.8 million).

On 24 September 2014, the Company paid a second interim dividend of 4.00 sen (2013: 3.41 sen) per share in respect of the financial year ended 31 December 2014 amounting to RM10.4 million (2013: RM8.8 million).

On 30 December 2014, the Company paid a third interim dividend of 8.00 sen (2013: 3.00 sen) per share in respect of the financial year ended 31 December 2014 amounting to RM20.7 million (2013: RM7.8 million).

For the fourth quarter, the Directors have declared a fourth interim dividend of 12.0 sen (2013: 6.20 sen) per share in respect of the financial year ended 31 December 2014. The dividend will be paid on 26 March 2015 to shareholders registered in the Register of Members at the close of business on 11 March 2015.

A9. Operating segments

Operating segment information for the year is as follows:

RM'000	Logistics and Distribution	Manufacturing	Eliminations	Total
2014				
Revenue				
External revenue	2,103,832	19,101	-	2,122,933
Inter-segment revenue	5,249	351,036	(356,285)	-
Total revenue	2,109,081	370,137	(356,285)	2,122,933
Results				
Segment results	53,775	95,461	(8,179)	141,057
Finance costs	(16,615)	(1,774)	1,621	(16,768)
Interest income	2,895	17	(1,621)	1,291
Profit before taxation	40,055	93,704	(8,179)	125,580
Taxation				(31,355)
Profit for the year				94,225
2013				
Revenue				
External revenue	1,945,949	690	-	1,946,639
Inter-segment revenue	2,902	320,842	(323,744)	-
Total revenue	1,948,851	321,532	(323,744)	1,946,639
Results				
Segment results	32,247	62,914	11,249	106,410
Finance costs	(14,485)	(2,497)	2,317	(14,665)
Interest income	3,559	10	(2,317)	1,252
Profit before taxation	21,321	60,427	11,249	92,997
Taxation				(36,236)
Profit for the year				56,761

A10. Carrying Amount of Revalued Assets

There has been no revaluation of property, plant and equipment during the current financial year.

A11. Subsequent Event

There was no subsequent event as at 23 February 2015 that will materially affect the financial statements of the financial year under review.

A12. Changes in the Composition of the Group

There was no change in the composition of the Group for the current financial year ended 31 December 2014 other than the acquisition of 75% equity interest in PT Errita Pharma during the year.

A13. Contingent Liabilities

No contingent liability has arisen since the financial year end.

A14. Commitments

The Group has the following commitments as at 31 December 2014:

	Authorised and contracted for RM'000	Authorised but not contracted for RM'000	Total RM'000
Property, plant and equipment	19,642	12,153	31,795
Intangible assets	4,230	-	4,230

A15. Financial Risk Management

All aspects of the Group's financial risk management objectives and policies are consistent with those disclosed in the financial statements as at and for year ended 31 December 2013.

A16. Intangible Assets

RM'000	Goodwill	Software	Capitalised development cost of work-in-progress	Pharmacy manufacturing licence and trade name	Rights to supply	Total
Cost						
At 1 January 2014	89,825	3,346	-	-	104,981	198,152
Additions	-	-	1,042	-	56,493	57,535
Acquisition of a subsidiary	48,848	-	-	18,879	-	67,727
Written off	-	-	-	-	(51,083)	(51,083)
Foreign exchange adjustments	654	192	-	551	-	1,397
At 31 December 2014	139,327	3,538	1,042	19,430	110,391	273,728
Accumulated amortisation						
At 1 January 2014	-	1,681	-	-	59,310	60,991
Amortisation charged	-	511	-	1,791	15,729	18,031
Written off	-	-	-	-	(51,083)	(51,083)
Foreign exchange adjustments	-	118	-	36	-	154
At 31 December 2014	-	2,310	-	1,827	23,956	28,093
Accumulated impairment						
At 1 January/31 December 2014	12,653	-	-	-	-	12,653
Net carrying value						
At 31 December 2014	126,674	1,228	1,042	17,603	86,435	232,982
At 31 December 2013	77,172	1,665	-	-	45,671	124,508

On 18 February 2014, the Group completed the acquisition of PT Errita Pharma ("PT Errita"). As of the date of this report, management has yet to finalise the purchase price allocation ("PPA") for the business combination, as required by MFRS 3 "Business Combination".

Management has 12 months from the date of the acquisition to complete the PPA exercise. Upon finalisation of the PPA, the Group will recognise any adjustments to the provisional goodwill arising from the acquisition in 2015. Based on the preliminary assessment, the goodwill on acquisition is estimated at RM48.8 million.

B17. Performance Review

Quarter 4 2014 vs Quarter 4 2013

For the quarter under review, the Group's revenue was RM627.1 million, a 10.4% increase from RM567.9 million in the corresponding period last year. The improved revenue and lower provision for doubtful debts have contributed to a higher current quarter Group profit before tax (PBT) of RM37.9 million compared with RM33.0 million in the previous year’s corresponding quarter.

Year ended 31 December 2014 vs Year ended 31 December 2013

For the financial year ended 31 December 2014, the Group's unaudited revenue increased by 10.5% to RM2.1 billion from RM1.9 billion last year on the back of stronger contributions from business operations.

The Group has recorded an unaudited PBT of RM125.6 million for the current financial year, representing a 35.1% jump from the RM93.0 million in prior year. The stellar performance was mainly contributed by steady growth in revenue coupled with reduced operating expenses, including amortisation and provision for doubtful debts.

The **Logistics and Distribution Division** current year's PBT of RM40.1 million saw a huge jump from RM21.3 million recorded in the previous year on the back of higher revenue and lower provision for doubtful debts.

Similarly, the **Manufacturing Division** posted a stronger PBT of RM85.5 million for the current year compared with RM71.7 million in the previous year. This was mainly attributable to improved margins following an increase in average selling price coupled with higher off-take for in-house products from government hospitals.

B18. Material Changes in Quarterly Results Compared to The Results of the Immediate Preceding Quarter

For the current quarter, the Group has achieved higher revenue of RM627.1 million, a 24.9% increase from RM502.1 million in the preceding quarter. This has enabled the Group to register a strong PBT of RM37.9 million in the current quarter, representing a substantial increase of 52.2% from RM24.9 million in the preceding quarter.

The **Logistics and Distribution Division** posted its strongest quarter performance in 2014 with a PBT of RM18.9 million, more than a three-fold increase from the RM4.9 million in the preceding quarter mainly attributable to higher demand from government hospitals.

The **Manufacturing Division's** PBT of RM19.0 million is on par with RM20.0 million in the preceding quarter.

B19. Prospects

As the Group moves into the new financial year, it remains optimistic of its business prospects. Given the current market trends and demand, the pharmaceutical sector in Malaysia continues to hold much potential for growth opportunities. The Group's Logistics and Distribution Division is expected to improve its performance while focusing on cost optimisation measures to maintain sustained earnings.

In line with the Group's business strategy, the Manufacturing Division will focus on product portfolio expansion and enhancements in its research and development efforts. The Division will continue its efforts via the on-going manufacturing improvement processes, along with collaborations with multinational companies in the European Union (EU) region via the Group's EU-certified plant.

The Group envisages stronger contribution from the manufacturing plant in Indonesia upon the completion of the acquisition and streamlining of activities in the plant. It is expected to contribute positively towards its long-term earnings, as it concentrates on exploring new viable business opportunities for organic and inorganic growth to sustain profitability for the new financial year.

B20. Notes on variance in actual profit and shortfall in profit guarantee

The disclosure requirements for explanatory notes for the variance of actual profit after tax and non-controlling interest and shortfall in profit guarantee are not applicable.

B21. Income Tax

	Current Period		Cumulative Period	
RM'000	**2014**	2013	**2014**	2013
Taxation based on profit for the period/year:				
- Current	**13,947**	10,004	**33,730**	33,779
- Deferred	**(14,195)**	3,836	**(4,444)**	9,969
	(248)	13,840	**29,286**	43,748
Under/(over) accrual in prior years:				
- Current	**1,481**	(2,100)	**2,069**	(7,512)
	1,233	11,740	**31,355**	36,236

B22. Corporate Proposal

a) Proposed joint venture

On 20 May 2013, the Company announced that a Joint Venture Agreement between Modern Healthcare Solutions Company Limited and Pharmaniaga Berhad ("Parties") had been signed to form and operate a joint venture limited liability company ("JV Company") in the Kingdom of Saudi Arabia. Upon the fulfillment of conditions precedent, the JV Company will be incorporated with each Party having a 50% equity interest in share capital of the JV Company.

On 17 November 2014, the Parties have agreed to further extend the validity of the JV Agreement for another six (6) months until 16 May 2015 or such later date as both Parties shall agree in writing to finalise the fulfilment of conditions precedent.

B22. Corporate Proposal (cont'd)

b) Supply Agreement

A Supply Agreement dated 13 February 2015 was entered into between Pharmaniaga Logistics Sdn Bhd ("PLSB") and Universiti Sains Malaysia ("USM") for the services of purchasing, storing, supplying and delivering to USM drugs and non-drugs as approved by USM ("Approved Products") and as specified therein. The Supply Agreement shall commence from 13 February 2015 and expire on 30 November 2019 ("Contract Period").

The value of the Approved Products to be supplied to USM is not stipulated in the Supply Agreement and is dependent on the actual volume, the agreed unit price of the Approved Products and scope of services rendered from time-to-time throughout the Contract Period.

B23. Borrowings and Debt Securities - Unsecured

	31 December 2014 RM'000	31 December 2013 RM'000
Current:		
Bankers' acceptances	**23,566**	50,805
Revolving credits	**115,000**	105,000
Short term foreign time loan	**60,968**	43,596
Hire purchase	**546**	161
	200,080	199,562
Non-current:		
Hire purchase	**1,060**	318

Short term foreign time loan of RM61.0 million (2013: RM43.6 million) is denominated in Indonesian Rupiah (IDR) and is equivalent to IDR216,199 million (2013: IDR162,067 million).

Included in bankers' acceptances is RM1.7 million (2013: Nil) is denominated in Indonesian Rupiah (IDR) and is equivalent to IDR6.0 million (2013: Nil).

B24. Realised and Unrealised Profits of the Group

The retained profits as at 31 December 2014 is analysed as follows:

	31 December 2014 RM'000	31 December 2013 RM'000
Total retained profits of the Group and its subsidiaries:		
- realised profits	**405,063**	373,704
- unrealised losses	**(8,819)**	(10,209)
	396,244	363,495
Less: Consolidation adjustments	**(9,194)**	(12,924)
Total Group retained profits as per consolidated accounts	**387,050**	350,571

B25. Additional Disclosures

	Current Period		**Cumulative Period**	
	2014 RM'000	2013 RM'000	**2014 RM'000**	2013 RM'000
Depreciation and amortisation	**14,694**	16,940	**49,724**	64,630
Provision for and write off of receivables	**260**	3,841	**3,844**	18,496
Provision for and write off of inventories	**2,119**	739	**13,260**	4,666
Impairment of goodwill	**-**	5,000	**-**	5,000
Impairment of investment in an associate	**19**	-	**19**	-
Foreign exchange loss	**819**	776	**803**	900

Other than the items mentioned above which have been included in the statement of comprehensive income, there were no impairment of assets, gain or loss on derivatives, gain or loss on disposal of subsidiaries and exceptional items included in the results for the year ended 31 December 2014.

B26. Economic Profit Statement

	Year ended 31 December	
	2014 RM'000	**2013 RM'000**
Economic profit	**23,769**	(2,196)

B27. Profit Forecast

No commentary is made on any variance between actual profit from forecast profit, as it does not apply to the Group.

B28. Earnings Per Share ("EPS")

	Current Period		Cumulative Period	
	2014	**2013**	**2014**	**2013**
Profit attributable to shareholders of the Company (RM'000)	**36,697**	20,813	**93,844**	55,200
Weighted average number of ordinary shares in issue ('000)	**258,883**	258,883	**258,883**	258,883
Basic and diluted earnings per share (sen)	**14.18**	8.04	**36.25**	21.32

B29. Authorised for Issue

The interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 23 February 2015.

By Order of the Board

Kuala Lumpur
23 February 2015

TASNEEM MOHD DAHALAN (LS0006966)